Thursday, May 02, 2019 8:53:44 PM
I’m not at all surprised with the reluctance, even resistance with which the medical research community disregards virtually all of the Anavex story. It’s something learned as an undergraduate science major. First, just lots of stuff to learn. So be sure to learn the “right stuff,” the material from the “right people.” The entire enterprise is run and controlled by the right people (expert professors) who have all the right information (theirs).
Undergrad science majors learn early on how to play the game. Ask the right kinds of questions. Don’t bring in any sort of external, unaccepted, or questionable information. Stay focused on what is actually known (meaning, what the professor believes). Aberrant, controversial, or hazy information or concepts that are put forth by an undergrad jeopardize his standing with the instructor. Stay focused and confined to what’s known. That demonstrates one to be a real student.
Then, science students have to learn how to conduct valid research. Validity, by and large, is demonstrated by generating statistically significant data. Be sure to demonstrate that derived experimental data have no more than a one in twenty chance (0.05) of being caused by chance, not the tested factors.
In short, the formal training of scientists simply does not in any way promote out of the box, new, or innovative thinking. The whole game is to keep investigations narrowly confined to what is known or understood; merely to more accurately substantiate existing bodies of knowledge. To conduct exciting new research in new areas, with new ideas dramatically lessens the chances of yielding statistically significant data. With out of range P values, the findings, arbitrarily, can not be accepted. Yes, the results might actually be correct; some really new things might have been demonstrated. But, who knows? Dare not take a chance with it.
Those are the constraints of undergrads and grad students doing their own research. But it’s exactly the same for doctoral and post-doctoral research. There is throughout modern science a decided pressure to restrain research to what it known; merely to more thoroughly confirm it. The consideration and testing of innovative, novel, and untested ideas can be career-jeopardizing.
Dozens of MDs and PhDs have read all of the Anavex research papers I have; even understood them better than I could. Privately, they know full well that the data, both murine and human, are valid; that the Anavex sigma-1 receptor agonists will yield profound therapeutic outcomes.
Why, then, no generalized acceptance or recognition of Anavex? Not enough people yet know. It’s not yet shared, mutually understood knowledge. For a PhD to state to her colleagues that Anavex is really on to something would evoke looks of alarm or astonishment. “What do you mean? That can’t be true. No molecule can rejuvenate a dysfunctional neuron. Get real.”
Since Hippocrates in the 4th century BCE medicine has always resisted new understandings. Of all the sciences, medical science has always been the most reluctant to change or accept new knowledge. “Nope, that’s not what my med school professor taught me; can’t be true. Alzheimer’s can’t be treated or prevented; period.”
Recent AVXL News
- Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/17/2024 11:30:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM